PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
6.44%
Growth of 6.44% versus flat Medical - Pharmaceuticals revenue. Walter Schloss would verify growth quality.
5.53%
Cost growth of 5.53% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify cost control.
10.34%
Growth of 10.34% versus flat Medical - Pharmaceuticals gross profit. Walter Schloss would verify quality.
3.67%
Margin change of 3.67% versus flat Medical - Pharmaceuticals margins. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
G&A reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate efficiency gains.
-100.00%
Marketing expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive implications.
-15.82%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
2.61%
Operating expenses growth exceeding 1.5x Medical - Pharmaceuticals median of 0.04%. Jim Chanos would check for waste.
5.09%
Total costs growth exceeding 1.5x Medical - Pharmaceuticals median of 0.90%. Jim Chanos would check for waste.
-15.38%
Interest expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-14.91%
D&A reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate efficiency.
32.32%
EBITDA change of 32.32% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
24.32%
Margin change of 24.32% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
35.65%
Income change of 35.65% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
27.45%
Margin change of 27.45% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-10.80%
Other expenses reduction while Medical - Pharmaceuticals median is -0.25%. Seth Klarman would investigate advantages.
32.47%
Income change of 32.47% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
24.46%
Margin change of 24.46% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
27.04%
Tax expense change of 27.04% versus flat Medical - Pharmaceuticals. Walter Schloss would verify strategy.
36.95%
Income change of 36.95% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
28.66%
Margin change of 28.66% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-31.52%
EPS decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-31.52%
Diluted EPS decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
100.00%
Share count change of 100.00% versus stable Medical - Pharmaceuticals. Walter Schloss would verify approach.
100.00%
Diluted share change of 100.00% versus stable Medical - Pharmaceuticals. Walter Schloss would verify approach.